- Home
- ATAI
as 11-20-2025 3:39pm EST
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
| Founded: | 2018 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTELVEEN |
| Market Cap: | 1.6B | IPO Year: | 2021 |
| Target Price: | $14.00 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $6.75 | Next Earning Date: | 11-12-2025 |
| Revenue: | $3,018,000 | Revenue Growth: | 811.78% |
| Revenue Growth (this year): | 736.04% | Revenue Growth (next year): | -91.20% |
Latest ATAI Life Sciences N.V. News
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Berenberg Upgrades ATAI Life Sciences to Buy From Positive, Price Target is $12
MT Newswires
a month ago
Atai Life Sciences Raises $149.5 Million From Public Offering
GlobeNewswire
a month ago
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Zacks
a month ago
atai Life Sciences (ATAI) Upgraded to Buy: Here's Why
Simply Wall St.
2 months ago
Why Atai Life Sciences (ATAI) Is in Focus After Positive Depression Data and $239M Shelf Registration Filing
Insider Monkey
4 months ago
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Zacks
4 months ago
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Insider Monkey
4 months ago
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating
Compare ATAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.